However, the NanoString data are confounded by vast differences among tumor sizes at the end of the 2-week treatment period (i.e., Fig. 4e) and do not elucidate the stage of combination treatment that PIM inhibition might be most critical for tumor growth inhibition or regression to occur. The gene discussed is PIM1; the disease is neoplasm.